FRANKFURT Oct 5 Stada, the German generic drugmaker whose chairman was ousted by disgruntled investors, said it was banking on branded products to underpin longer term growth.
The company said on Wednesday that its target of group sales of 5 percent on average per year until 2019 would be driven by 8 percent growth per year at the branded products business, which makes brand-name prescription drugs that have lost patent protection as well as branded non-prescription drugs...
13:09 JCPenney shuttering up to 140 stores as sales weaken, more sluggish growth seen ahead18
15:45 Warren Buffett rails against fee-hungry Wall Street managers17
18:41 U.S. home sales hit 10-year high, prices soar20
18:32 Magic Johnson takes over the Lakers, ousts Mitch Kupchak and Jim Buss in stunning front-office shakeup18